Javascript must be enabled to continue!
GRANT OPPORTUNITIES OF THE EUROPEAN INNOVATION COUNCIL "EIC TRANSITION" PROGRAM
View through CrossRef
The article discusses the grant opportunities of the European Innovation Council EIC Transition program. Its main goals, priorities, and capabilities are demonstrated. An analysis of the features of attracting its financial instruments for Ukrainian innovators was carried out. It is emphasized that the EIC Transition program supports innovative activities with grant resources that go beyond experimental proof-of-principle in the laboratory. Projects applying for EIC Transition funding should address both technology and market/business development, possibly including iterative learning processes based on early customer or user feedback. 2 types of competitions were explored, namely: EIC Transition Open and EIC Transition Challenges. It is emphasized that the financing of EIC Transition Open projects is carried out to ensure the support of any technologies and innovations related to various sciences, technologies, industries, and the financing of EIC Transition Challenges projects takes place in accordance with strategic challenges, in which the goals, expected results and impact are previously are defined by the program as important. It was demonstrated that in 2023 the following areas were prioritized: full-scale micro-nano-bio devices for medicine and medical research; environmental intelligence; optical frequency combs based on microcircuits. The paper outlines the expected results of the EIC Transition project: a technology that has demonstrated its effectiveness for the intended application (TRL 5/6) and a business model, its initial validation and a business plan for its development in the market. It is emphasized that the amount of grant funding is up to 2.5 million euros and can be 100% of the cost of eligible project costs for testing and demonstrating the technology in an appropriate environment and developing market readiness. It is summarized that participants in EIC Transition projects can be: individual applicants (SMEs, start-up spin-offs, research organizations, universities) or a consortium (3-5 partners), they can receive a grant for the implementation of ideas for the maturation and testing of new technology in laboratory and in relevant applied environments, as well as the development of a business model for the future commercialization of the innovation.
Title: GRANT OPPORTUNITIES OF THE EUROPEAN INNOVATION COUNCIL "EIC TRANSITION" PROGRAM
Description:
The article discusses the grant opportunities of the European Innovation Council EIC Transition program.
Its main goals, priorities, and capabilities are demonstrated.
An analysis of the features of attracting its financial instruments for Ukrainian innovators was carried out.
It is emphasized that the EIC Transition program supports innovative activities with grant resources that go beyond experimental proof-of-principle in the laboratory.
Projects applying for EIC Transition funding should address both technology and market/business development, possibly including iterative learning processes based on early customer or user feedback.
2 types of competitions were explored, namely: EIC Transition Open and EIC Transition Challenges.
It is emphasized that the financing of EIC Transition Open projects is carried out to ensure the support of any technologies and innovations related to various sciences, technologies, industries, and the financing of EIC Transition Challenges projects takes place in accordance with strategic challenges, in which the goals, expected results and impact are previously are defined by the program as important.
It was demonstrated that in 2023 the following areas were prioritized: full-scale micro-nano-bio devices for medicine and medical research; environmental intelligence; optical frequency combs based on microcircuits.
The paper outlines the expected results of the EIC Transition project: a technology that has demonstrated its effectiveness for the intended application (TRL 5/6) and a business model, its initial validation and a business plan for its development in the market.
It is emphasized that the amount of grant funding is up to 2.
5 million euros and can be 100% of the cost of eligible project costs for testing and demonstrating the technology in an appropriate environment and developing market readiness.
It is summarized that participants in EIC Transition projects can be: individual applicants (SMEs, start-up spin-offs, research organizations, universities) or a consortium (3-5 partners), they can receive a grant for the implementation of ideas for the maturation and testing of new technology in laboratory and in relevant applied environments, as well as the development of a business model for the future commercialization of the innovation.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
P-501. Implementation of an Active Congenital Cytomegalovirus Screening Program in a Large Pediatric Hospital System. Key Findings and Lessons Learned
P-501. Implementation of an Active Congenital Cytomegalovirus Screening Program in a Large Pediatric Hospital System. Key Findings and Lessons Learned
Abstract
Background
Congenital cytomegalovirus (cCMV) infection is the most common congenital infection. Cleveland Clinic...
Editorial Affiliation and Subconscious Bias in High-Impact Ophthalmology Journals
Editorial Affiliation and Subconscious Bias in High-Impact Ophthalmology Journals
Background: Editorial leadership plays a critical role in shaping the scientific literature. Transitions in editors-in-chief (EICs) may introduce subconscious biases, particularly ...
Innovation, Innovation Strategy, and Strategic Innovation
Innovation, Innovation Strategy, and Strategic Innovation
Abstract
Purpose
The purposes of this chapter are to propose definitions of innovation, product innovation, business mode...
Innovation ambidexterity effects on product innovation performance: the mediating role of decentralization
Innovation ambidexterity effects on product innovation performance: the mediating role of decentralization
PurposeThe purpose of the study was to analyse the impact of innovation ambidexterity represented by explorative and exploitative innovation capabilities and their combined effects...

